AEDG PeptidevsDSIP

AEDG peptide (Ala-Glu-Asp-Gly) is the minimal active sequence of Epithalon and represents the core tetrapeptide responsible for its reported biological effects. According to the Khavinson peptide bioregulator theory, this short sequence has tissue-specific gene-regulatory activity, particularly targeting pineal gland cells and somatic cells capable of telomerase expression.

The primary reported mechanism is activation of telomerase, the ribonucleoprotein enzyme that maintains telomere length. AEDG is proposed to interact with regulatory elements in the hTERT gene promoter (encoding the catalytic subunit of telomerase), enhancing its transcription in somatic cells where hTERT is normally silenced or minimally expressed. Reactivation of telomerase allows cells to add TTAGGG telomeric repeats to chromosome ends, counteracting the progressive telomere shortening that occurs with each cell division and ultimately triggers replicative senescence. Cell culture studies from the Khavinson laboratory have reported that AEDG treatment extends the replicative lifespan of human fibroblasts and increases telomerase activity in peripheral blood mononuclear cells.

The second major reported mechanism involves regulation of pineal gland function. The pineal gland produces melatonin — the circadian rhythm hormone and potent antioxidant — and its function declines markedly with age (pineal calcification and reduced melatonin output). AEDG is proposed to modulate gene expression in pinealocytes, restoring melatonin synthesis toward more youthful levels. This would have downstream effects on circadian rhythm regulation, sleep quality, antioxidant defense, and immune function — all of which are modulated by melatonin. Additional reported effects include upregulation of antioxidant enzyme expression (SOD, catalase) and modulation of cell cycle regulatory genes. As with other Khavinson peptide bioregulators, the research base is predominantly from Russian institutions, and the proposed direct DNA-binding mechanism awaits independent validation.

Delta Sleep-Inducing Peptide is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from rabbit cerebral venous blood during electrically induced sleep in 1977. Despite decades of research, its precise molecular receptor has not been definitively identified, making DSIP unusual among well-studied peptides. However, its physiological effects have been extensively characterized.

DSIP's sleep-promoting mechanism involves modulation of the balance between excitatory (glutamatergic) and inhibitory (GABAergic) neurotransmission in sleep-regulating brain regions. It enhances GABAergic tone in the ventrolateral preoptic area (VLPO) — the brain's primary sleep-promoting nucleus — while reducing glutamatergic excitatory drive in wake-promoting areas like the lateral hypothalamus and locus coeruleus. The net effect is promotion of slow-wave (delta) sleep, characterized by high-amplitude, low-frequency (0.5-4 Hz) EEG oscillations. This is the deepest, most restorative sleep stage, during which growth hormone secretion peaks, memory consolidation occurs, and cellular repair processes are most active.

Beyond sleep, DSIP has significant neuroendocrine effects. It reduces cortisol secretion by suppressing corticotropin-releasing hormone (CRH) and ACTH release, lowering the activity of the hypothalamic-pituitary-adrenal (HPA) stress axis. This stress-reducing effect may itself contribute to sleep quality, as HPA axis hyperactivity is a common cause of insomnia and fragmented sleep. DSIP also modulates endogenous opioid signaling — it has been studied in opiate withdrawal protocols for its ability to normalize disturbed endorphin/enkephalin balance. Some research suggests it may regulate somatostatin release and interact with the orexin/hypocretin system, though these mechanisms are less well established. The paradox of DSIP is that despite its very short plasma half-life (15-25 minutes), sleep-promoting effects persist for hours, suggesting it triggers sustained changes in neural network activity or gene expression rather than requiring continuous receptor occupancy.